Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Pharmacokinetics of Co-encapsulated Antiretrovirals with Ingestible Sensors.

Liu H, Daar ES, Wang Y, Siqueiros L, Campbell K, Shen J, Guerrero M, Ko MW, Xiong D, Dao J, Young T, Rosen M, Fletcher C.

AIDS Res Hum Retroviruses. 2019 Sep 13. doi: 10.1089/AID.2019.0202. [Epub ahead of print]

PMID:
31516025
2.

Pharmacokinetics of Co-Formulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate After Switch From Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Healthy Subjects.

Ramanathan S, Custodio JM, Wei X, Wang H, Fordyce M, Dave A, Ling KH, Szwarcberg J, Kearney BP.

J Acquir Immune Defic Syndr. 2016 Jul 1;72(3):281-8. doi: 10.1097/QAI.0000000000000959.

PMID:
26885802
3.

An indirect comparison of efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir and dolutegravir + abacavir/lamivudine.

Rogatto F, Bouee S, Jeanbat V, Piontkowsky D, Aragao F, Bosse M.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19779. doi: 10.7448/IAS.17.4.19779. eCollection 2014.

4.

Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trials.

Hagins D, Orkin C, Daar ES, Mills A, Brinson C, DeJesus E, Post FA, Morales-Ramirez J, Thompson M, Osiyemi O, Rashbaum B, Stellbrink HJ, Martorell C, Liu H, Liu YP, Porter D, Collins SE, SenGupta D, Das M.

HIV Med. 2018 Nov;19(10):724-733. doi: 10.1111/hiv.12664. Epub 2018 Aug 12.

5.

Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV-infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine.

Cid-Silva P, Fernández-Bargiela N, Margusino-Framiñán L, Balboa-Barreiro V, Mena-De-Cea Á, López-Calvo S, Vázquez-Rodríguez P, Martín-Herranz I, Míguez-Rey E, Poveda E, Castro-Iglesias Á.

Basic Clin Pharmacol Toxicol. 2019 Apr;124(4):479-490. doi: 10.1111/bcpt.13161. Epub 2018 Dec 7.

PMID:
30388308
6.

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks.

Sax PE, DeJesus E, Mills A, Zolopa A, Cohen C, Wohl D, Gallant JE, Liu HC, Zhong L, Yale K, White K, Kearney BP, Szwarcberg J, Quirk E, Cheng AK; GS-US-236-0102 study team.

Lancet. 2012 Jun 30;379(9835):2439-2448. doi: 10.1016/S0140-6736(12)60917-9. Erratum in: Lancet. 2012 Aug 25;380(9843):730.

PMID:
22748591
7.

Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection.

Cohen C, Elion R, Ruane P, Shamblaw D, DeJesus E, Rashbaum B, Chuck SL, Yale K, Liu HC, Warren DR, Ramanathan S, Kearney BP.

AIDS. 2011 Mar 27;25(6):F7-12. doi: 10.1097/QAD.0b013e328345766f.

PMID:
21412057
8.

Plasma and intracellular pharmacokinetics of tenofovir in patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide.

Podany AT, Bares SH, Havens J, Dyavar SR, O'Neill J, Lee S, Fletcher CV, Swindells S, Scarsi KK.

AIDS. 2018 Mar 27;32(6):761-765. doi: 10.1097/QAD.0000000000001744.

9.

Tenofovir alafenamide, emtricitabine, elvitegravir, and cobicistat combination therapy for the treatment of HIV.

Imaz A, Podzamczer D.

Expert Rev Anti Infect Ther. 2017 Mar;15(3):195-209. doi: 10.1080/14787210.2017.1286736. Epub 2017 Feb 8.

PMID:
28117606
10.

Strength in Amalgamation: Newer Combination Agents for HIV and Implications for Practice.

McCoy C, Badowski M, Sherman E, Crutchley R, Smith E, Chastain DB; Society of Infectious Diseases Pharmacists.

Pharmacotherapy. 2018 Jan;38(1):86-107. doi: 10.1002/phar.2055. Epub 2017 Dec 11. Review.

PMID:
29105160
11.

Brief Report: Urine Emtricitabine and Tenofovir Concentrations Provide Markers of Recent Antiretroviral Drug Exposure Among HIV-Negative Men Who Have Sex With Men.

Haaland RE, Martin A, Livermont T, Fountain J, Dinh C, Holder A, Lupo LD, Hall L, Conway-Washington C, Kelley CF.

J Acquir Immune Defic Syndr. 2019 Nov 1;82(3):252-256. doi: 10.1097/QAI.0000000000002133.

PMID:
31335590
12.

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial.

DeJesus E, Rockstroh JK, Henry K, Molina JM, Gathe J, Ramanathan S, Wei X, Yale K, Szwarcberg J, White K, Cheng AK, Kearney BP; GS-236-0103 Study Team.

Lancet. 2012 Jun 30;379(9835):2429-2438. doi: 10.1016/S0140-6736(12)60918-0.

PMID:
22748590
13.

Choice of the initial antiretroviral treatment for HIV-positive individuals in the era of integrase inhibitors.

Alejos B, Suárez-García I, Bisbal O, Iribarren JA, Asensi V, Górgolas M, Muga R, Moreno S, Jarrín I; CoRIS cohort.

PLoS One. 2019 Aug 26;14(8):e0221598. doi: 10.1371/journal.pone.0221598. eCollection 2019.

14.

Combinational therapies for HIV: a focus on EVG/COBI/FTC/TDF.

Schrijvers R, Debyser Z.

Expert Opin Pharmacother. 2012 Sep;13(13):1969-83. doi: 10.1517/14656566.2012.712514. Epub 2012 Jul 31. Review.

PMID:
22849516
15.

Short Communication: Bioequivalence of Tenofovir and Emtricitabine After Coencapsulation with the Proteus Ingestible Sensor.

Ibrahim ME, Brooks KM, Castillo-Mancilla JR, McHugh C, Morrow M, Brothers J, MaWhinney S, Hosek S, Huhn G, Anderson PL.

AIDS Res Hum Retroviruses. 2018 Oct;34(10):835-837. doi: 10.1089/AID.2018.0081. Epub 2018 Sep 5.

16.

Drug-Drug Interaction Studies Between Hepatitis C Virus Antivirals Sofosbuvir/Velpatasvir and Boosted and Unboosted Human Immunodeficiency Virus Antiretroviral Regimens in Healthy Volunteers.

Mogalian E, Stamm LM, Osinusi A, Brainard DM, Shen G, Ling KHJ, Mathias A.

Clin Infect Dis. 2018 Aug 31;67(6):934-940. doi: 10.1093/cid/ciy201.

PMID:
29522076
17.

Real-World Assessment of Renal and Bone Safety among Patients with HIV Infection Exposed to Tenofovir Disoproxil Fumarate-Containing Single-Tablet Regimens.

Nkhoma ET, Rosenblatt L, Myers J, Villasis-Keever A, Coumbis J.

PLoS One. 2016 Dec 12;11(12):e0166982. doi: 10.1371/journal.pone.0166982. eCollection 2016.

19.

Cost-effectiveness of DTG + ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United States.

Peng S, Tafazzoli A, Dorman E, Rosenblatt L, Villasis-Keever A, Sorensen S.

J Med Econ. 2015;18(10):763-76. doi: 10.3111/13696998.2015.1046878.

PMID:
25934146
20.

Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 through 48 weeks of treatment.

Wilkins EL, Cohen CJ, Trottier B, Esser S, Smith DE, Haas B, Brinson C, Garner W, Chuck S, Thorpe D, De-Oertel S.

AIDS Care. 2016;28(3):401-8. doi: 10.1080/09540121.2015.1096890. Epub 2015 Oct 21.

PMID:
26489045

Supplemental Content

Support Center